Opinion

Video

Bladder Cancer: Treatment Options and Managing Adverse Effects

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Related Videos
2 experts in this video
2 experts in this video
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Renal Cell Carcinoma | stock.adobe.com
December 13th 2024

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

NDI-101159 in Heavily Pretreated RCC
December 3rd 2024

NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

ALLO-316 in Advanced CD70-Positive ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 27th 2024

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs | Image Credit: © Katsyarina - stock.adobe.com
November 22nd 2024

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs